Hikma to acquire Canadian assets of Teligent

Hikma is set to add strength to its portfolio with an acquisition that marks its expansion into Canada.

The company is acquiring the Canadian assets of Teligent for $45.75 million. The transaction is expected to be completed before the end of the first quarter of 2022.

[Read more: Hikma intros Kloxxado]

The acquisition includes a portfolio of 25 sterile injectable products, three in-licensed ophthalmic products and a pipeline of seven additional products, four of which are approved by Health Canada.

“This acquisition further expands our portfolio of essential sterile injectable medicines and gives Hikma an entry into the highly attractive Canadian injectables market,” Riad Mishlawi, president of Hikma Injectables, said. “The combination of our sales and marketing expertise and this portfolio of exciting products will enable us to expand our North American business and develop a solid position in this important market.”

[Read more: Hikma to acquire Custopharm]

In October 2021, Teligent filed for voluntary protection under Chapter 11 of the U.S. Bankruptcy Code. 

As part of this process, Teligent initiated a sale of its core assets, following which Hikma has agreed to acquire Teligent’s Canadian assets.